
Role of Community Pharmacies in Chronic Disease Management

Fahad Nabi¹, Mohd Altaf Dar^{2*}

^{1,2*}Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.

Corresponding Email: ^{2*}daraltaf490@gmail.com

Received: 30 March 2022

Accepted: 21 June 2022

Published: 29 July 2022

Abstract: *Chronic diseases, which include diabetes, hypertension, and asthma, are among the main causes of morbidity and death around the globe. As a result, appropriate management techniques are required in order to enhance the results for patients and lower the costs associated with healthcare. Through the provision of easily available healthcare services, medication management, patient education, and lifestyle counseling, community pharmacies play a crucial part in the management of chronic diseases. The purpose of this research is to investigate the many roles that community pharmacies play in the management of chronic diseases, as well as the benefits and problems that are associated with their involvement, and the tactics that may be utilized to intensify their influence. Using their accessibility and knowledge to their advantage, community pharmacists have the potential to make a major contribution to the overall efficiency of the healthcare system as well as to the improvement of health outcomes.*

Keywords: *Community Pharmacies, Chronic Disease Management, Medication Adherence, Patient Education, Healthcare Access.*

1. INTRODUCTION

Diseases that are chronic, such as diabetes, hypertension, asthma, and cardiovascular disease, are among the most prevalent health disorders in the world. These diseases present enormous difficulties to healthcare systems and have an impact on the quality of life for millions of people. Continuous monitoring, adherence to medicine, change in lifestyle, and patient education are all necessary components for effective therapy of these disorders. Since the beginning of time, primary care physicians and specialists have been the ones responsible for managing chronic diseases. However, the increasing prevalence of chronic diseases calls for a more integrated strategy that involves a variety of healthcare practitioners [1-3]. In the management of chronic diseases, community pharmacists are in a position to play a key role because of their accessibility and the regular encounters they have with patients. Medication



therapy management (MTM), patient education, lifestyle counseling, and monitoring of clinical indicators are some of the services that pharmacists, given their expertise in medication, are able to offer as a means of supplementing the care that physicians deliver. Through their participation, patients may experience increased adherence to their prescription regimens, improved disease control, and improved outcomes. The incorporation of community pharmacists into the management of chronic diseases presents a number of problems, despite the potential advantages. These challenges include limited reimbursement for services, the good effects of blood pressure monitoring programs that were led by pharmacists were emphasized in a study. These programs led to significant reductions in blood pressure levels and improved hypertension control. Additionally, it has been demonstrated that the participation of pharmacists in the management of asthma, which includes the monitoring of peak flow data and the modification of inhaler strategies, can enhance asthma control and prevent exacerbations from the condition. Increasing the presence of community pharmacists in collaborative care a limited scope of practice that varies from region to region, and the requirement for increased training and collaboration with other healthcare practitioners. The existing responsibilities that community pharmacies play in the management of chronic diseases are investigated in this review. The benefits and difficulties associated with their participation are also identified, and several ways to improve their contribution to public health are investigated [3-7].

2. RELATED WORKS

The management of medication therapy, often known as MTM, is an essential component of the services that community pharmacists offer in the diagnosis and treatment of chronic diseases. Through the use of comprehensive medication reviews, the identification of drug-related issues, and the formulation of tailored care plans, medication therapy management (MTM) aims to maximize the utilization of medicine. Studies have demonstrated that medication therapy management (MTM) services offered by pharmacists have the potential to considerably improve medication adherence, decreased the number of adverse drug events, and improved clinical outcomes in patients who suffer from chronic diseases. As an illustration, a study discovered that improving glycemic control and lowering HbA1c levels in diabetic patients through the use of MTM services led by pharmacists contributed to the improvement of these outcomes [7-10]. According to the findings of yet another study, the utilization of MTM services for hypertensive patients resulted in improved control of blood pressure and a decreased risk of cardiovascular disease [11]. Community pharmacists are in an excellent position to give patients with education and counseling regarding lifestyle choices, both of which are critical components of the management of chronic diseases. Through one-on-one conversations, pharmacists are able to educate patients about their diseases, the significance of taking medications as prescribed, the possibility of experiencing adverse effects, and the necessity of making changes to their lifestyles, such as changing their food and engaging in physical activity. It has been found that educational interventions carried out by pharmacists are connected with increased self-management abilities as well as improved health outcomes. For instance, it has been demonstrated that diabetes education programs led by pharmacists can improve patients' self-monitoring of blood glucose levels,



increase their knowledge of diabetes, and encourage them to make healthier lifestyle choices. Pharmacists are also able to provide clinical examinations and monitoring in order to provide help for the management of chronic diseases. This involves taking measurements of clinical factors such as blood pressure, blood glucose levels, cholesterol, and other similar measurements. It is possible for pharmacists to discover early indicators of illness development or problems by regular monitoring, which enables timely intervention and modifications to treatment strategies [11-15]. The good effects of blood pressure monitoring programs that were led by pharmacists were emphasized in a study. These programs led to significant reductions in blood pressure levels and improved hypertension control. Additionally, it has been demonstrated that the participation of pharmacists in the management of asthma, which includes the monitoring of peak flow data and the modification of inhaler strategies, can enhance asthma control and prevent exacerbations from the condition. Increasing the presence of community pharmacists in collaborative care models has the potential to improve the management of chronic diseases. Pharmacists are able to collaborate with physicians, nurses, and other healthcare providers to provide complete care through the use of collaborative practice agreements (CPAs) and team-based care techniques. The utilization of such models makes communication and coordination easier, which in turn guarantees that patients receive care that is both holistic and ongoing. Collaborative treatment that includes pharmacists has been shown to result in improved clinical results and increased patient satisfaction, according to research. For instance, a research discovered that patients with diabetes who received treatment from a multidisciplinary team that included a pharmacist achieved better glucose control and had fewer hospitalizations compared to those who received the standard treatment [15-17].

3. METHODOLOGY

To conduct this review, an extensive search was performed across several academic databases, including PubMed, Google Scholar, and Scopus. The search utilized keywords such as "community pharmacies," "chronic disease management," "medication adherence," "patient education," and "collaborative care." The selection criteria focused on research and studies that explored the roles of community pharmacists in managing chronic diseases. This included evaluating the benefits and drawbacks of their involvement and identifying methods to enhance their impact. The review aimed to present a thorough overview of the current involvement of community pharmacists in chronic disease management. By analyzing findings from a variety of sources, the review incorporated evidence from recent studies and best practices in the field to highlight strategies and solutions for improving the role of community pharmacists. This approach ensured that the recommendations were grounded in the latest research and effective practices. One key aspect highlighted in the review is the critical role community pharmacists play in managing chronic diseases. They are often the most accessible healthcare professionals and can provide essential services such as medication counseling, monitoring of drug therapy, and patient education. These services are particularly vital for chronic disease patients, who require ongoing management and support to achieve optimal health outcomes. The review also examined the benefits of community pharmacists' involvement in chronic disease management. These benefits include improved



medication adherence, better disease control, and enhanced patient satisfaction. Pharmacists can offer personalized care and education, which can lead to a better understanding of disease management and medication use among patients. Additionally, pharmacists can identify and resolve medication-related issues, which can prevent complications and hospitalizations. However, the review also identified several challenges that community pharmacists face in chronic disease management. These challenges include limited access to patient health records, time constraints, and lack of reimbursement for clinical services. Addressing these challenges is crucial to maximizing the impact of community pharmacists in chronic disease management. The review suggests several strategies to enhance the role of community pharmacists. One such strategy is to provide pharmacists with better access to patient health records, enabling them to make more informed decisions about patient care. Another strategy is to advocate for policy changes that allow pharmacists to be reimbursed for clinical services, recognizing their contributions to patient health. Additionally, integrating pharmacists into collaborative care teams can enhance communication and coordination among healthcare providers, leading to better patient outcomes. Education and training are also essential for empowering community pharmacists to take on a more significant role in chronic disease management. Continuing education programs and professional development opportunities can equip pharmacists with the knowledge and skills needed to manage chronic diseases effectively. Furthermore, raising awareness about the importance of pharmacists' role among other healthcare providers and the public can foster greater collaboration and utilization of pharmacists' expertise. The review emphasizes the need for a supportive environment that allows community pharmacists to utilize their full potential in chronic disease management. This includes providing adequate resources, training, and support to help pharmacists overcome the barriers they face. By doing so, pharmacists can contribute more effectively to the management of chronic diseases, ultimately improving patient outcomes and reducing healthcare costs. The review underscores the significant impact community pharmacists can have on chronic disease management. By leveraging their accessibility and expertise, pharmacists can play a crucial role in improving medication adherence, patient education, and overall disease management. Addressing the challenges they face and implementing strategies to enhance their role can lead to better health outcomes for patients with chronic diseases. The findings of this review highlight the importance of empowering community pharmacists to take on a more active role in chronic disease management, ensuring that they can provide high-quality care to their patients.

4. RESULTS AND DISCUSSION

In order to effectively manage chronic diseases, community pharmacists often adopt medication therapy management, often known as MTM. This is one of the most effective strategies. In addition to providing continuing patient monitoring and education, MTM services include comprehensive medication evaluations, the detection and treatment of drug-related issues, and the monitoring of patients. According to the findings of research, medication therapy management (MTM) services result in increased drug adherence, less medication mistakes, and improved clinical results. As an illustration, a study that investigated the effects of MTM services on patients with diabetes found that these services



resulted to considerable improvements in glycemic control, with many patients reaching their desired levels of HbA1c [17-20]. There have been significant decreases in both blood pressure and cardiovascular risk factors that have been demonstrated by MTM programs for hypertension that are implemented by pharmacists. Counseling patients about the significance of adhering to prescribed therapy, potential adverse effects, and interactions between medications is another component of the MTM services. The risk of complications and hospitalizations associated with chronic diseases can be reduced with the assistance of pharmacists. This is accomplished by ensuring that patients comprehend their treatment regimens and the significance of adhering to them. The management of chronic diseases requires a number of components, including patient education and counseling on lifestyle choices [22-25]. Community pharmacists are in a good position to deliver education about disease states, medication use, and lifestyle adjustments because of the numerous encounters they have with patients. Educational activities like this are absolutely necessary in order to provide patients with the ability to effectively manage their diseases [26]. Pharmacists are able to provide individualized guidance on a variety of lifestyle issues, including food, exercise, quitting smoking, and other factors that influence the outcomes of chronic diseases. It has been demonstrated that educational programs that are led by pharmacists can improve patients' understanding about their diseases, boost their ability to self-manage, and encourage healthier behaviors. It has been found that diabetes education programs that are led by pharmacists are related with greater patient understanding of diabetes, improved self-monitoring of blood glucose levels, and enhanced adherence to advice regarding diet and exercise. A similar effect has been seen when hypertensive patients receive lifestyle counseling from pharmacists, which has resulted in improved blood pressure control and a decreased risk of cardiovascular disease. In order to provide assistance with the treatment of chronic diseases, community pharmacists are becoming increasingly involved in the monitoring of clinical parameters and the conduct of assessments. By performing routine monitoring of clinical indicators such as blood pressure, blood glucose, cholesterol levels, and other parameters, it is possible to detect the progression of the disease or problems at an earlier stage [26-30]. Monitoring programs that are conducted by pharmacists have been shown to have positive effects on the treatment of patient chronic diseases. It has been demonstrated that regular monitoring of blood pressure by pharmacists is related with significant reductions in blood pressure levels as well as improved control of hypertension. The participation of pharmacists in the management of asthma has resulted in improved asthma control and a reduction in the number of exacerbations. This has been accomplished by monitoring peak flow values and changing inhaler strategies. Pharmacists are able to conduct point-of-care testing for illnesses such as diabetes and hyperlipidemia, in addition to monitoring patients. This allows for early interventions and revisions to treatment plans [30-32]. The overall quality of treatment is improved as a result of these services, which also contribute to improved health outcomes for patients who are patients with chronic conditions. Community pharmacists should be incorporated into collaborative care models in order to improve the management of chronic diseases. This is because such models encourage coordinated and comprehensive care. In order to provide holistic treatment, pharmacists are able to collaborate with physicians, nurses, and other healthcare providers through the use of collaborative practice agreements (CPAs) and team-based care techniques. The efficacy of



collaborative care approaches that involve pharmacists has been demonstrated by research. Patients who receive care from multidisciplinary teams that include pharmacists have been proven to experience better clinical results and higher levels of satisfaction, according to studies. As an illustration, a study discovered that patients with diabetes who participated in a collaborative care model achieved better glucose control and had fewer hospitalizations in comparison to those who received the standard care. Additionally, collaborative care models make it easier for healthcare practitioners to communicate with one another and coordinate their efforts, which guarantees that patients receive care that is both continuous and integrated. The contributions that pharmacists provide to the management of medications, the education of patients, and the monitoring of their progress are essential components of these models, which enhance the overall effectiveness of the management of chronic diseases [32-37].

5. CONCLUSION

When it comes to the management of chronic diseases, community pharmacies play a crucial role. They are able to provide key healthcare services by utilizing their accessibility, competence, and frequent interactions with patients. Pharmacists make a contribution to increased medication adherence, better disease control, and enhanced patient outcomes through the administration of drug therapy, the education of patients, the counseling of lifestyle choices, and clinical assessments. Despite the enormous benefits, integrating community pharmacy into the management of chronic diseases presents a number of hurdles. These challenges include restricted funding, regulatory barriers, and the requirement for greater collaboration with other healthcare professionals. It is essential, in order to maximize the impact that community pharmacies have on the management of chronic diseases, to address these problems through initiatives such as extending training, incorporating pharmacists into collaborative care models, and using technology. Increasing the autonomy of community pharmacists and removing the obstacles they encounter are two ways in which the healthcare system can improve the quality of care provided to patients who suffer from chronic diseases, as well as improve the outcomes for public health and lower the costs of healthcare. There is no question that community pharmacies play a crucial part in the management of chronic diseases, and the contributions they provide are absolutely necessary in order to achieve improved health outcomes for patients and communities.

6. REFERENCES

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. *International journal of adolescent medicine and health*. 2021 Jul 22; 34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. *Alexandria journal of medicine*. 2017 Jul 11; 53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. *International Journal of Adolescent Medicine and Health*. 2021 Jun 18; 33(6):339-45.



4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. *Breast Cancer: Targets and Therapy*. 2022 Jan 11:15-24
5. Rasool S, Maqbool M. An overview about *Hedychium spicatum*: a review. *Journal of Drug Delivery and Therapeutics*. 2019 Feb 15; 9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. *Asian Journal of Pharmaceutical Research and Development*. 2019 Feb 15; 7(1):66-9.
8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. *International journal of adolescent medicine and health*. 2021 Apr 21; 33(6):333-7.
9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. *Journal of Drug Delivery and Therapeutics*. 2019 May 15; 9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. *Annals of Medicine and Surgery*. 2021 Dec 1; 72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. *Journal of Drug Delivery and Therapeutics*. 2019 Mar 15; 9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. *Open Health*. 2022 May 2; 3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. *International journal of adolescent medicine and health*. 2021 Jul 22; 34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of *Nigella sativa* L., a wonder herb. *Journal of Applied Pharmaceutical Sciences and Research*. 2020; 3(4):04-13.
15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2018 Sep 1; 5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. *CELLMED*. 2021; 11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. *International Journal of Research in Pharmaceutical Sciences and Technology*. 2020 May 18; 1(3):95-101.
18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:8-18.
19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care



- Hospital in Srinagar, Jammu and Kashmir, India. *Journal of Pharmaceutical Research International*. 2021 Jun 10; 33(31A):135-40.
20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2019 Jan 1; 6(1):983-7.
 21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. *Open Health*. 2022 Jan 1; 3(1):114-9.
 22. Bashir R, Maqbool M, Ara I, Zehravi M. An Insight into Novel Drug Delivery System: In Situ Gels. *CELLMED*. 2021; 11(1):6-1.
 23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. *International Journal of Adolescent Medicine and Health*. 2022 Sep 19; 35(1):15-9.
 24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. *Journal of Pharmaceutical Research & Reports*. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022; 127.
 25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8254-9.
 26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8163-+.
 27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8070-6.
 28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8060-5.
 29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):357-66.
 30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. *The Indian Journal of Nutrition and Dietetics*. 2021 Jul: 408-18.
 31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. *Interventional Pain Medicine and Neuromodulation*. 2021 Dec 31; 1(1).
 32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:19-31.
 33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. *Journal of Pharmacy Practice and Community Medicine*. 2018; 4(4).



34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):357-66.
35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8070-6.
36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8163-+.
37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8254-9.